Floatz logo

Ruxolitinib

Philadelphia Positive Acute Lymphoblastic Leukemia

University Health Network, TorontoSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Philadelphia Positive Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →